Nearly a mile underground in South Dakota, scientists are building a world-leading experiment to study neutrinos and investigate some of the universe's greatest mysteries, including how the universe took shape after the Big Bang and if neutrinos are the reason our world is predominantly made of matter. Currently, crews from Fermilab, CERN and SURF are assembling large steel beams to form the outer structure of the neutrino experiment's massive detector modules.

Batavia, Illinois, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Installation crews with the U.S. Department of Energy's (DOE) Fermi National Accelerator Laboratory (Fermilab) and CERN, the European Organization for Particle Physics, are working alongside the Sanford Underground Research Facility (SURF) to begin building massive cryostats, giant insulated containers designed to hold liquid argon at an extremely cold temperature, for the leading-edge Deep Underground Neutrino Experiment (DUNE).

The work is happening nearly a mile underground at SURF in Lead, South Dakota, where thousands of red steel beams were meticulously transported, one by one, from the surface down to the assembly area. Once installed, the beams will form the outer structures of the experiment's two detector module cryostats. Each will house approximately 17,000 tons of liquid argon maintained at approximately minus 300 degrees Fahrenheit.

"DUNE is Fermilab's top priority," said Norbert Holtkamp, director of Fermilab. "The entire organization is thrilled to see this work begin. Once underway, DUNE has the potential to help us broaden our fundamental understanding of our universe, as well as potentially open the door to new technological advances."

Once operational, Fermilab will send a beam of neutrinos 800 miles (1,300 kilometers) through Earth to DUNE's liquid-argon detectors in South Dakota. A second detector near the neutrino beam source at Fermilab will measure the particles before they begin their journey. Together, the facilities at Fermilab and the underground site in South Dakota form the Long-Baseline Neutrino Facility.

DUNE is an international collaboration of over 1,500 researchers hosted by Fermilab, including five DOE Office of Science Laboratories. The more than 6,200 tons of steel being used on the cryostat modules are an in-kind contribution from CERN. CERN is leading the design, construction planning, logistics and installation of DUNE's massive cryostats, working with a Minnesota-based structural steel contractor to assemble the structures deep underground in South Dakota.

"We have been lucky to see several milestones occur recently, such as the arrival of steel for both cryostats in Rapid City from Houston, to the celebration earlier this year marking the start of steel being lowered underground in Lead," said Jolie Macier, project manager for the far detectors and cryogenics of DUNE. "This brings us one step closer to science."

The DUNE experiment marks the first time CERN has made such significant contributions to an experiment happening outside of Europe.

 "Collaboration is in CERN's DNA, and our contribution to DUNE is a brilliant example of cross-organizational partnership," said Mark Thomson, director general of CERN. "After years of planning and careful coordination, I am thrilled to see that we are ready to start installation."

CERN is a leader in particle physics technologies, including the design of the unique cryostats for DUNE. Using its Neutrino Platform facility, CERN developed and built the ProtoDUNE detector, the first prototype of the two detector technologies that will be used in the DUNE far detector modules.

"The work that has been done is a full contribution of CERN's expertise," said Llu?s Miralles, Neutrino Platform principal project engineer at CERN. "Not only did we contribute our technical know-how, but also the project management capabilities of the organization. CERN demonstrates here how, by design, we have in-house competencies to address requirements and challenges at all levels of the project."   

Each cryostat measures 216 feet long (65.8 meters), 62 feet wide (18.9 meters) and 60 feet high (18.3 meters). To illustrate the enormous size of the cryostats, each one is longer than a Boeing 747 airplane, and each one will stand a full story taller than the iconic Hollywood sign in Los Angeles.

"SURF is proud to support this world-class research 4,850 feet (1,478 meters) below ground level. This massive experiment is slated to run into the late 2040s, with the potential to impact science for generations. In the process, it's creating a home for some of the best and brightest scientific minds in the world and a range of high-paying jobs right here in the Black Hills," said Mike Headley, SURF laboratory director and executive director of the South Dakota Science and Technology Authority.

A total of 2,600 red steel beams will be used to build DUNE's two cryostat modules. SURF is responsible for shaft operations and logistics, ensuring that each of these steel beams - and other necessary installation equipment - is safely transported underground to the work site.

In addition to the installation work underway in the South Cavern, SURF crews have begun lowering steel components for the second cryostat into the North Cavern, where assembly is expected to begin next year.

"This marks an incredible milestone for the collaboration and reflects the cross-continental partnerships between CERN, Fermilab, and SURF that are essential to realizing this project," said Sowjanya Gollapinni, co-spokesperson for DUNE. "This synergy is at the core of how big international collaborations work. We are thrilled to take this major step forward as we move closer to the transformative science that DUNE will deliver."

The underground space of DUNE is planned to be completed by 2029, and the detector apparatus in 2030. From that date, a 1,500-strong worldwide team of researchers will begin probing the laws of nature more deeply than ever before, observing particles from the Sun and outer space. Using Fermilab's PIP-II accelerator upgrade, the terrestrial neutrino beam is expected to be sent to the underground detectors in South Dakota by 2031, enabling DUNE's long-term scientific program.

Fermi National Accelerator Laboratory is America's national laboratory for particle physics and accelerator research. Fermi Forward Discovery Group manages Fermilab for the U.S. Department of Energy Office of Science. Visit Fermilab's website at www.fnal.gov and follow us on social media.

Copyright 2026 GlobeNewswire, Inc.

*New program helps AI-native startups build and scale with Zoom's industry-leading speech, language, and voice AI Services, no equity stake required; applications open today

SAN JOSE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) today announced AI Launchpad, a new grant program offering eligible startups up to $150,000 in Zoom AI Services credits to build and scale next-gen AI-native applications - completely equity-free.

Removing the costly barrier posed by multi-vendor APIs, the program provides founders with access to the AI technology used in Zoom's own products, plus technical support to accelerate go-to-market growth.

"AI startups should spend time solving real problems, not stitching together infrastructure," said X.D. Huang, chief technology officer at Zoom. "AI Launchpad gives founders the same industry-leading AI technology that powers our own products, plus resources to move faster and focus their engineering talent where it matters most."

Building AI-powered products often forces startups to stitch together a patchwork of expensive third-party providers for speech, language, and decision-making. AI Launchpad helps eliminate this hurdle by providing a unified platform, so developers can spend more time building their products and less time managing the technology behind them.

The program builds on Zoom AI Services, which delivers Zoom's AI capabilities to developers through standalone APIs. These services span speech recognition, summarization, translation, voice AI, and decision intelligence, so developers can build applications that better understand conversations, generate responses, and take action. AI Launchpad extends Zoom's investment in AI infrastructure to emerging companies developing new products across industries.

Helping startups build with Zoom AI Services

AI Launchpad gives startups access to Zoom AI Services, a platform that brings speech, language, and decision-making capabilities together without requiring developers to build and manage each component themselves.

Startups can use Zoom's APIs to develop a range of AI-powered products, including:

Voice AI and customer service agents that understand spoken requests, generate natural responses, and support customer interactions.

Conversation intelligence applications that transcribe and summarize calls, meetings, and other audio to surface useful information and support follow-up workflows.

Multilingual experiences that use translation and speech capabilities to help people communicate across languages.

AI-powered workflows that use the Decisions API to analyze information, classify requests, and help determine the next action.

The program offers three tiers based on a startup's stage, technical needs, and eligibility:

Credits are available for up to 12 months. Participating startups may also receive engineering guidance, opportunities to showcase their products through Zoom's developer channels, and introductions to potential enterprise customers.

Applications now open

AI Launchpad is designed for startups developing software products with speech, language, or conversational AI at their core. Applicants will be evaluated based on their product, team, technical approach, traction, and plans to build with Zoom AI Services.

Applications will be reviewed on a rolling basis, with a limited number of startups accepted into the program.

To learn more about AI Launchpad and apply, visit https://zoom.ai/ai-launchpad.

About Zoom

Zoom (NASDAQ:ZM) is a system of action for modern work, turning live collaboration into completed results. From entrepreneurs to global enterprises, customers choose Zoom to seamlessly collaborate, communicate, and drive outcomes across meetings, phone, contact center, and more - all with the built-in assistance of Zoom AI. Founded in 2011, Zoom is headquartered in San Jose, CA. For more information, visit zoom.com.

Copyright 2026 GlobeNewswire, Inc.

NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- KraneShares today announced that the private investments held by the KraneShares Public-Private AI & Technology ETF (Ticker: AGIX), including Anthropic, have contributed meaningfully to the fund's performance since launch. AGIX became the first ETF to invest directly in Anthropic in February 2025, at a $61.5 billion valuation.?

Since AGIX's inception on 7/17/2024 through 10/31/2026, AGIX has returned +70.13% versus the Nasdaq-100 Index's return of +45.64%.2 AGIX's private exposure contributed +11.92 percentage points to its total return.2 Overall, AGIX outperformed a widely recognized technology benchmark by +24.49 percentage points.2

This update comes as Anthropic, maker of Claude, moves toward the public markets after filing with the US Securities and Exchange Commission on Oct. 26 to list on Nasdaq under the ticker symbol "ANT."3

"Anthropic showed what's possible when a fund like AGIX can get onto the cap table of a category-defining AI company early, and our goal is to keep finding the next opportunities like it," said Derek Yan, CFA, Senior Investment Strategist at KraneShares. "Since that investment, we've continued to build out AGIX's private holdings across robotics, photonics, autonomy, and AI-native platforms. The public core is designed to do the heavy lifting on day-to-day risk, while our private allocation gives us room to be selective and add companies we believe could become the next major value drivers in the AI cycle."

"The AI cycle is creating value in both public and private markets, and some of the most important innovation is happening at companies that haven't gone public yet," said James Maund, KraneShares Head of Capital Markets and Portfolio Manager of AGIX. "We built AGIX so investors wouldn't have to choose between the two. Pairing a public AI core with direct stakes in leaders like Anthropic gives investors a way to participate in this shift as it unfolds, not just after these companies reach the public markets."

Building on AGIX's Anthropic investment, it has continued to add direct stakes in private companies across the AI landscape and today holds positions in General Intuition, Ayar Labs, Standard Bots, Apptronik, Nuro, and Polymarket.

For more information on the KraneShares Public-Private AI & Technology ETF (Ticker: AGIX), top 10 holdings, and its innovative structure, please visit our AI ETF AGIX overview page.

About KraneShares

KraneShares delivers research-driven, high-conviction strategies connecting investors to the world's most powerful growth themes. From emerging technologies, China's dynamic capital markets, carbon credits, alternatives, and income, the firm offers differentiated exposures designed to capture the megatrends reshaping the global economy.

Holdings are subject to change.

For AGIX top 10 holdings, risks, standard performance, and other fund information, please click here.

Citations:

Data from Bloomberg and KraneShares as of 10/27/2026.

Data from Bloomberg as of 10/31/2026.

The Wall Street Journal, Anthropic Unveils Paperwork for Blockbuster IPO, October 26, 2026.

Carefully consider the Funds' investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Funds' full and summary prospectus, which may be obtained by visiting www.kraneshares.com. Read the prospectus carefully before investing.

Risk Disclosures:

Investing involves risk, including possible loss of principal. There can be no assurance that a Fund will achieve its stated objectives. Indices are unmanaged and do not include the effect of fees. One cannot invest directly in an index.

This information should not be relied upon as research, investment advice, or a recommendation regarding any products, strategies, or any security in particular. This material is strictly for illustrative, educational, or informational purposes and is subject to change. Certain content represents an assessment of the market environment at a specific time and is not intended to be a forecast of future events or a guarantee of future results; material is as of the dates noted and is subject to change without notice.

AGIX may invest in derivatives, which are often more volatile than other investments and may magnify AGIX's gains or losses. A derivative (i.e., futures/forward contracts, swaps, and options) is a contract that derives its value from the performance of an underlying asset. The primary risk of derivatives is that changes in the asset's market value and the derivative may not be proportionate, and some derivatives can have the potential for unlimited losses. Derivatives are also subject to liquidity and counterparty risk. AGIX is subject to liquidity risk, meaning that certain investments may become difficult to purchase or sell at a reasonable time and price. If a transaction for these securities is large, it may not be possible to initiate, which may cause AGIX to suffer losses. Counterparty risk is the risk of loss in the event that the counterparty to an agreement fails to make required payments or otherwise comply with the terms of the derivative.

AI-exposed companies face profitability challenges due to high research costs, competition, IP reliance, and regulatory risk. Product failures or safety concerns could be detrimental. Identifying AI companies accurately is complex. Tech firms face risks of product failure, obsolescence, regulatory impact, and uncertain profitability due to technological advancements and government policies.

Certain tech investments may lack current profitability and future success is uncertain. AGIX is subject to non-U.S. issuers risk, which may be less liquid than investments in U.S. issuers, may have less governmental regulation and oversight, are typically subject to different investor protection standards than U.S. issuers, and the economic instability of the non-U.S. countries. Fluctuations in currency of foreign countries may have an adverse effect to domestic currency values. AGIX may invest in Initial Public Offerings (IPOs).

Securities issued in IPOs have no trading history, and information about the companies may be available for very limited periods. In addition, the prices of securities sold in IPOs may be highly volatile. In addition, as AGIX increases in size, the impact of IPOs on AGIX's performance will generally decrease.

Large capitalization companies may struggle to adapt fast, impacting their growth compared to smaller firms, especially in expansive times. This could result in lower stock returns than investing in smaller and mid-sized companies. In addition to the normal risks associated with investing, investments in smaller companies typically exhibit higher volatility. AGIX is new and does not yet have a significant number of shares outstanding.

If AGIX does not grow in size, it will be at greater risk than larger funds of wider bid-ask spreads for its shares, trading at a greater premium or discount to NAV, liquidation and/or a trading halt. AGIX may invest in privately-issued and private company securities, which are generally not registered, may carry resale restrictions, and often lack active markets.

These investments can be less liquid, harder to value, and subject to larger price swings, which may result in delays or higher costs when buying or selling. Private companies may have limited operating histories, smaller or less established businesses, fewer financial resources, and less available information. They may be more vulnerable to competition, market conditions, or economic downturns. A liquid market for their securities may never develop, and IPOs, if they occur, can be volatile and may negatively affect AGIX's investment.

Narrowly focused investments typically exhibit higher volatility. AGIX's assets are expected to be concentrated in a sector, industry, market, or group of concentrations to the extent that the Underlying Index has such concentrations. The securities or futures in that concentration could react similarly to market developments. Thus, AGIX is subject to loss due to adverse occurrences that affect that concentration. A large number of shares of AGIX are held by a single shareholder or a small group of shareholders. Redemptions from these shareholders can harm Fund performance, especially in declining markets, leading to forced sales at disadvantageous prices, increased costs, and adverse tax effects for remaining shareholders. AGIX is non-diversified.

ETF shares are bought and sold on an exchange at market price (not NAV) and are not individually redeemed from the Fund. However, shares may be redeemed at NAV directly by certain authorized broker-dealers (Authorized Participants) in very large creation/redemption units. The returns shown do not represent the returns you would receive if you traded shares at other times. Shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns.

Beginning 12/23/2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn't available, the midpoint between the national best bid and national best offer ("NBBO") as of the time the ETF calculates the current NAV per share. Prior to that date, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time.

The KraneShares ETFs and KFA Funds ETFs are distributed by SEI Investments Distribution Company (SIDCO), 1 Freedom Valley Drive, Oaks, PA 19456, which is not affiliated with Krane Funds Advisors, LLC, the Investment Adviser for the Funds, or any sub-advisers for the Funds.

Copyright 2026 GlobeNewswire, Inc.

Now available to order in Europe, the Metabolon Verus Metabolomics Profiling Kit delivers results in just five days, with human and rodent blood sample types and proven reproducibility across eight independent laboratories

MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Metabolon, Inc., the global leader in metabolomics solutions advancing life sciences research, diagnostics, therapeutics, and precision medicine, today announced that the Metabolon Verus Metabolomics Profiling Kit is now available to order in Europe in addition to the US, with expanded validation beyond the previously supported human plasma, serum, and urine matrices to now include rodent plasma and serum.

The expanded sample-matrix validation broadens the kit's utility for both human and non-human research applications. Additional validation against reference datasets demonstrated accuracy and precision in metabolite identification and quantification across the newly supported matrices, providing researchers with greater confidence in metabolomics results generated from different sample types. Together with the kit's established workflow, these capabilities enable laboratories worldwide to investigate biochemical changes across a wider range of experimental designs, biological models, and sample-collection protocols.

"The real value of the Metabolon Verus Kit is the ability to scale metabolomics without necessarily expanding the team. For core facilities like ours, analyzing hundreds of samples efficiently while maintaining high-quality, consistent data and minimizing batch effects is critical. The standardized workflow and streamlined data processing help reduce turnaround time, allowing us to spend less time processing data and more time interpreting the biological findings. Ultimately, this enables us to support larger studies and deliver meaningful insights to our collaborators faster," said Hardik Shah, Metabolomics Platform Director at the University of Chicago Comprehensive Cancer Center.

The Metabolon Verus? Metabolomics Profiling Kit delivers results in five days via integrated sample preparation, automated metabolite annotation, and access to Metabolon's Integrated Bioinformatics Platform. By combining a standardized laboratory workflow with Metabolon's data-processing infrastructure and scientific expertise, the kit enables researchers to establish and scale metabolomics capabilities within their own laboratories while maintaining access to the resources needed for consistent, reproducible results. A reference library covering more than 1,500 metabolites across 100 biochemical sub-pathways supports diverse research applications, while built-in quality controls help ensure data consistency and simplify downstream analysis.

European availability builds on Metabolon's Early Access Program, which involved 10 laboratories across five countries. Participants applied the kit to research spanning microbiome biology, stem cell transplantation, and neurological and pulmonary conditions. Their feedback helped refine training, implementation, and customer support for broader international adoption. An international ring trial across eight independent laboratories further demonstrated the kit's reproducibility, identifying an average of 735 metabolites across 90 biochemical pathways per human plasma sample set, with 89% metabolite overlap between sites. Metabolite abundances correlated strongly with expert-curated reference datasets (median coefficient of 0.91), while fed-versus-fasted biological findings remained consistent across laboratories.

"European availability of the Metabolon Verus Metabolomics Profiling Kit, together with expanded support for rodent plasma and serum, represents an important step in making high-quality metabolomics more accessible to researchers worldwide," said Ro Hastie, CEO of Metabolon. "By broadening the range of validated sample types while giving laboratories greater control over study execution, we are enabling researchers to apply metabolomics across a range of human and non-human studies. These advancements make it easier for organizations to bring metabolomics in-house and incorporate biochemical insights into their broader multiomics research programs."

With US and now European availability, expanded sample-matrix support, and demonstrated interlaboratory reproducibility, the kit makes high-quality, in-house metabolomics more accessible for preclinical, translational, and multiomics research.

The Metabolon Verus Metabolomics Profiling Kit is now available to order in Europe in addition to the US. To learn more or place an order, visit www.metabolon.com/metabolon-verus-metabolomics-profiling-kit/.

About Metabolomics

Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete, current-state functional readout of that system. Metabolomics helps researchers see beyond individual genetic variation, capturing the combined impact of genetic and external factors, such as drugs, diet, lifestyle, and the microbiome, on human health.​

By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy. ​Metabolomics anchors multiomic discovery in biological function, helping organizations reduce uncertainty and make more confident scientific and business decisions.

About Metabolon

Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 25 years of metabolomics leadership, 15,000+ projects, 4,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technological, and bioinformatics techniques. Metabolon's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library, while Metabolon's expanding portfolio of solutions enables researchers to access Metabolon-standard metabolomics through both centralized services and in-house workflows.

The Metabolon Verus Metabolomics Profiling Kit extends Metabolon's validated methods into laboratories worldwide, enabling researchers with LC-MS capabilities to generate standardized, reproducible metabolomics data on-site through streamlined workflows, embedded quality controls, automated metabolite annotation, and direct access to Metabolon's Integrated Bioinformatics Platform. Metabolon's industry-leading data, translational science, and bioinformatics expertise help customers and partners resolve some of the most challenging questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable metabolomics and multiomics solutions-from discovery and targeted services to decentralized in-house metabolomics-that support customer needs across academic research, biopharma, core facilities, and CROs, from early discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and X.

Copyright 2026 GlobeNewswire, Inc.

Demonstrates new evolution in mRNA to address rare conditions

CDMO's work with parent-led, patient-focused foundation will investigate a development pathway to combat CDKL5 Deficiency Disorder

AGC Biologics is well positioned to help advance mRNA programs toward the clinic

HEIDELBERG, Germany, Nov. 10, 2026 (GLOBE NEWSWIRE) -- In a world where patients with CDKL5 deficiencies can suffer 40 to 60 epileptic seizures a day, a contract biopharmaceutical manufacturer and a parent-founded foundation will partner on early-stage messenger RNA development to find a long-term treatment for the rare neurodevelopmental disease.

With few RNA-based programs in development for rare diseases, Child's Cure Genetic Research and AGC Biologics will collaborate to identify a viable path for a new mRNA therapeutic that mimics the protein made by the CDKL5 gene.

The intent of the protein-sustaining treatment is to reduce seizures, improve neurological development, and help patients-many of whom are babies and young children-gain control from debilitating symptoms that impede their health and potential.

This early proof-of-concept work within AGC Biologics' integrated mRNA solutions will seek to identify the best pathway toward clinical development.

New rare disease frontier for mRNA

Cyclin-dependent kinase-like 5 deficiency disorder is a rare genetic disease caused by mutations or deletions of the CDKL5 gene. Current treatment for the disorder often only consists of supportive care, though the foundation is also exploring a small molecule drug that is presently in clinical trials.

For young patients like Reyna Jogani, advancement is not happening at the speed she needs to get the critical CDKL5 protein that enables routine brain activity related to movement, learning, vision, and behavior. Reyna's father, and Child's Cure co-founder, Jainu Jogani, has embraced the rapid advancement and potential of mRNA development, and this partnership with AGC Biologics aims to uncover a sustaining treatment for the rare disease.

RNA-based therapeutic programs are also in development for rare neurodevelopmental diseases such as Rett and Angelman syndromes. Child's Cure is pursuing mRNA for CDKL5 deficiency disorder as part of an effort to help advance the application of this approach to rare diseases.

mRNA therapy will complement gene therapy

Through this program, Child's Cure will explore mRNA as a potential complement to a one-time adeno-associated virus gene therapy intended to address the mutated or deleted CDKL5 gene. The mRNA therapy development will explore how to provide ongoing protein replacement infusions and could offer another option for patients with differing needs, including those for whom gene therapy may not be suitable.

"What I've learned about CDKL5 deficiency disorder is that one treatment approach may not meet every patient's needs. Gene therapy may not be an option for every patient, and questions remain about how long a one-time treatment effect will last," said Jogani. "Investing further in a complementary approach through mRNA intends to restore the missing CDKL5 protein by offering a redosable, adjustable way to support ongoing protein replacement. We are leaving no stone unturned to explore what might help."

AGC Biologics' support for early-phase mRNA programs

In 2023, AGC Biologics leveraged 40 years of experience in microbial fermentation as well as expanded plasmid DNA capabilities to create its new messenger RNA service line at its Heidelberg, Germany site. The mRNA process development services provide custom approaches to meet each specific mRNA need and can produce mRNA supply from R&D to GMP grades.

"Similar to what we've established across decades in other modalities, we are invested in delivering early-stage clinical expertise to developers with mRNA candidates looking to translate their discovery into commercial success," said Christoph Winterhalter, Chief Business Officer of AGC Biologics. "This is an inflection point for this market, where it is progressing into new arenas including personalized medicines and gene therapy. Our experts are the best in the marketplace to support this growth and expansion."

In November 2025, AGC Biologics announced it would partner with Repair Biotechnologies to develop and manufacture a novel mRNA therapy designed to combat the build-up of atherosclerotic plaques, a major contributor to cardiovascular disease, the leading cause of human mortality.

In 2027, AGC Biologics will also offer mRNA process development and commercial production at its newest location in Yokohama, Japan.

Frequently Asked Questions (FAQs):

Why is Child's Cure exploring mRNA alongside gene therapy for CDKL5 deficiency disorder?

The approaches are intended to serve different roles. The AAV gene therapy is intended to address the mutated or deleted CDKL5 gene, while the mRNA program is intended to provide the CDKL5 protein that patients are missing. Child's Cure is exploring mRNA as a potential complementary or alternative approach because gene therapy may not be suitable for every patient, and the long-term durability of a one-time gene therapy remains an important question. Repeatable mRNA dosing to restore CDKL5 protein production could provide another way to support patients over time, subject to further development and clinical evidence.

What experience does AGC Biologics have in working with rare disease therapeutics?

Amidst a complicated landscape for rare conditions with small patient populations, therapy development demands innovation and new ways of thinking. Organizations tackling some of the rarest of diseases are choosing AGC Biologics because of its ability to support unconventional development models:

AGC Biologics is a part of the Orphan Therapeutics Accelerator, a non-profit biotech focused on completing development and enabling commercial access to stalled rare disease treatments.

In 2025, AGC Biologics partnered with public benefit corporation, Rarity PBC, to provide end-to-end manufacturing services for Rarity's gene therapy for ADA-SCID, an immunodeficiency disorder also known as "Bubble Baby Disease."

When WASKYRA was approved in December 2025, Fondazione Telethon became the first non-profit organization to receive FDA approval of a gene therapy, with AGC Biologics as its chosen manufacturer.

AGC Biologics has produced multiple FDA-approved therapies already in commercial supply, with additional programs currently under review. This track record makes AGC Biologics an ideal partner for a broad range of organizations, from public benefit corporations to non-profits and institutions funded by public initiatives.

What experience does AGC Biologics have in mRNA development and manufacturing?

In 2023, AGC Biologics established its mRNA platform services in Heidelberg, Germany, where it already had a longstanding commercial plasmid DNA operation serving multiple customers. This services expansion also leveraged four decades of microbial manufacturing in addition to pDNA to develop its mRNA production capabilities.

Which AGC Biologics sites have mRNA services?

AGC Biologics offers mRNA development and manufacturing services in Europe and Asia at its Heidelberg mRNA Center of Excellence in Germany and Yokohama site in Japan.

About Child's Cure Genetic Research

Child's Cure Genetic Research is a parents-founded organization dedicated to developing innovative, precision treatment opportunities for rare genetic disorders in children. Driven by the urgent need to find cures, the organization envisions a future where every child has access to transformative treatments that offer hope for a better tomorrow. Through cutting-edge research and strategic collaborations, Child's Cure is committed to reshaping the future of pediatric rare disease care. Through cutting-edge research, Child's Cure is committed to reshaping the future of pediatric rare disease care-and actively welcomes strategic collaborations across other pediatric genetic conditions.

About AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.

Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.

Copyright 2026 GlobeNewswire, Inc.

*Boehringer Ingelheim progresses to 6th place in the 2026 Access to Medicine Index

*Company performs above average across all three assessed areas, with significant progress in Governance of Access and Product Delivery

*Long-term health equity initiatives, partnerships, open innovation and stronger outcome measurement contribute to continued progress

Ingelheim, Germany - Boehringer Ingelheim has advanced to 6th place in the 2026 Access to Medicine Index (ATMI), continuing its rise from 13th in 2022 and 8th in 2024. This result recognizes the company's sustained progress to improving access to healthcare in low- and middle-income countries and reflects an approach that increasingly combines access to medicines with stronger health systems, local capabilities and research partnerships.

Every two years the ATMI evaluates the efforts of the world's leading pharmaceutical companies and ranks the top 20 based on their efforts to improve access to medicine in low- and middle-income countries. Boehringer performed above average across all three areas assessed by the Index, with particularly strong progress in Product Delivery, the area with the highest weighting. This reflects strong advancement of the company's approach to access, from expanding initiatives and long-term partnerships to open innovation and stronger impact measurements.

"Access to healthcare is not achieved through a single intervention. It requires long-term collaboration to strengthen research, healthcare capabilities, and enabling access to treatment in underserved communities, where significant gaps remain. Our progress in the ATMI is important recognition; however, what matters most is translating that progress into better health outcomes for more people," said Augusto Muench, Head of Sustainability at Boehringer.

Highlighted progress in this year's assessment includes:

More comprehensive access strategies for cardio-renal-metabolic medicines, improving availability and affordability in low- and middle-income countries through approaches such as Access to Healthcare in Kenya.

Long-term partnerships and capacity building initiatives in Sub-Saharan Africa, including the expanded partnership with the Botswana Vaccine Institute and support for social entrepreneurs and start-ups with focus on healthcare through business incubator and accelerator programs and impact investments.

CRM Patient Africa, a long-term initiative launched in 2025 and currently underway in Kenya, Rwanda and Ghana, combining research capacity building, screening and diagnostics, healthcare professional trainings and efforts to support access to medicines.

Growing global health initiatives, including Stop Rabies and Angels, continue to expand their reach. The Angels Initiative works together with ambulance crews, nurses, doctors, and hospitals to build stroke-ready networks and have reached over 28 million stroke patients to date.

Open science through opnMe, strengthening R&D capacity through collaboration with academic researchers. Since the last assessment, research partners from countries covered by the Index have authored or co-authored over 15 new scientific publications.

More robust outcome measurement supports stronger tracking and reporting and validates how access and health-system-strengthening initiatives are reaching more patients.

These achievements reflect the continued progress since Boehringer Ingelheim's strategic pivot towards health equity in 2023. "Expanding access is only part of the picture. We also need to understand whether our work is delivering meaningful and lasting change," shared Dr. James Kinniburgh, global MORE HEALTH lead at Boehringer. Adding, "Stronger measurement gives us the evidence to better understand what works, lessons learned to strengthen our approach and ultimately, direct our efforts where they can make the biggest difference."

As Boehringer Ingelheim continues to advance its health equity strategy and initiatives, the company reaffirms its commitment to meaningful collaboration with global health organizations, local partners, and underserved communities to support greater accessibility and affordability to healthcare, worldwide.

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective. Our approximately 54,300 employees serve over 130 markets to build a healthier tomorrow. Learn more at www.boehringer-ingelheim.com.

About the Access to Medicine Index

The Access to Medicine Index analyses 20 of the largest research-based pharmaceutical companies with products for high-burden diseases in low- and middle-income countries. It ranks them on their efforts to improve access to medicine, identifies best practices, highlights where progress is being made and uncovers where critical action is still required.

The Index is endorsed by over 145 investors, collectively managing assets worth over USD 22 trillion. It is published every two years by the Access to Medicine Foundation, an independent non-profit organisation funded by the Gates Foundation, the Leona M. and Harry B. Helmsley Charitable Trust, Wellcome Trust, UK Foreign, Commonwealth and Development Office and the Dutch Ministry of Foreign Affairs. Learn more: www.accesstomedicinefoundation.org

Copyright 2026 GlobeNewswire, Inc.

LIDKOPING, Sweden, Nov. 10, 2026 (GLOBE NEWSWIRE) -- ASKO Professional made its first-ever appearance at Expodetergo International 2026 in Milan, marking an important step in bringing its Scandinavian approach to professional laundry and garment care to the international textile care industry.

From 23 to 26 October, ASKO Professional presented an integrated portfolio of professional washing machines, tumble dryers, the One Care Cabinet and connected services, alongside its professional dishwashing solutions. The showcase demonstrated how Swedish engineering, robust construction and Scandinavian design can support demanding commercial environments where hygiene, efficiency and reliability are essential.

Professional laundry

ASKO Professional washing machines combine advanced hygiene features with durable construction and high spin efficiency. Steel Seal, a rubber-free door design, reduces bacterial growth by up to 95% compared with traditional rubber door seals. Stainless-steel construction, dedicated disinfection programmes and Quattro Construction further support hygienic, stable and reliable operation.

Professional tumble dryers feature Sensi Dry moisture sensing to automatically stop drying at the selected level, helping prevent unnecessary over-drying. Butterfly Drying keeps garments separated to promote even and gentle drying.

A different approach to garment care

The One Care Cabinet refreshes garments that do not require a full wash, combining controlled steam, gentle drying and advanced filtration to reduce odours and wrinkles. Its Quick Refresh programme takes approximately 20 minutes, providing a practical solution for garments that need to be quickly returned to use.

Professional dishwashing

ASKO Professional also presented its professional dishwashing range. Robust 8 Steel construction is combined with dedicated hygiene programmes, flexible loading and fast cycles. SANI programmes deliver verified hygienic performance, while selected programmes can clean dishes in as little as 29 minutes.

Smarter, connected professional care

Connected services were another important part of ASKO Professional's Expodetergo debut. ConnectLife Pro gives businesses a central overview of appliances, programmes and consumption across one or multiple locations. Pro Link allows appliance data to be integrated into existing business systems for applications such as performance monitoring and maintenance planning.

ASKO Professional's first participation at Expodetergo demonstrated its ambition to bring Scandinavian design, Swedish engineering and intelligent technology to a broader professional audience, with solutions designed around the people and businesses that rely on them every day.

About ASKO

Built to endure and thoughtfully enhance everyday living. ASKO Professional develops durable laundry and dishwashing solutions for demanding commercial environments.

Copyright 2026 GlobeNewswire, Inc.

Expanding go-to-market and technical investment to help joint customers worldwide scale agentic AI with the Denodo Platform on AWS

PALO ALTO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Denodo, the AI data layer company, announced that it has signed a multi-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS). The agreement is focused on helping enterprises develop and scale agentic AI on a foundation of real-time, governed data across hybrid and multi-cloud environments.

The SCA builds on the existing relationship between AWS and Denodo and marks a new phase of investment to accelerate adoption of the Denodo Platform on AWS worldwide. Key initiatives include:

Workshops to help customers identify high-value agentic AI use cases and design solutions grounded in their enterprise data

Co-marketing events and campaigns to educate customers about the Denodo Platform on AWS and generate demand

Field alignment and co-selling to help customers evaluate, deploy, and scale agentic AI

Commercial incentives to support customer technical evaluations and AWS Marketplace purchases

Solution offerings with systems integrators for agentic business processes, such as fraud prevention in banking, claims processing in insurance, and predictive maintenance in manufacturing

"Agentic AI can transform how enterprises operate, but the data that powers it remains highly fragmented, and traditional architectures were never designed for the real-time demands of autonomous agents," said ?ngel Vi?a, CEO of Denodo. "Together with AWS, we give joint customers a unified AI data layer so that agents can access live, governed data and active context across every enterprise source, without moving or replicating it. This expanded collaboration helps our customers move from pilot to production in days rather than months, and scale with confidence."

"AI agents are increasingly making decisions and taking actions autonomously, making it critical for organizations to establish the right data foundation to support their AI systems," said Allison Johnson, Director of Americas Technology Partners at AWS. "Our collaboration with Denodo helps customers extend the value of their AWS AI investments across their entire data estate, connecting AWS model hosting, agent orchestration, and monitoring services with current, operational data and context wherever it resides. This helps organizations get more from AWS AI services while grounding agents in trusted context for accurate decisions and reliable actions."

With Denodo's SaaS or self-managed solutions, joint customers can get more value from their AWS AI and analytics investments by extending Amazon Bedrock AgentCore, Amazon Quick, Amazon SageMaker, and other AWS services to enterprise data that resides across on-premises, SaaS, sovereign, and multi-cloud environments. With zero-copy delivery, organizations can give AI agents and analytics access to trusted, governed business context without waiting for every dataset to be migrated or replicated through new integration pipelines. Rather than building a new data access path for each agent or use case, teams can reuse the same governed data products, semantic definitions, and access policies across multiple agents and applications, helping them move faster from individual AI initiatives to enterprise-wide adoption.

"At Bayer Crop Science, Latin America, we use Denodo and AWS to gain real-time, governed access to distributed data and unified semantics across our cloud and on-premises systems. This has enabled our business to gain insights faster, support mission-critical workloads, and reduce data replication costs," said Eric Carvalho, Data Architecture Manager at Bayer. "We reduced the time our teams spent searching for data by 80% using AWS solutions, powered by trusted context from Denodo's AI data layer. We now have autonomous customer service and tracking agents in production."

Denodo is an AWS ISV Accelerate Partner with a SaaS co-sell eligible solution and holds multiple AWS competencies, including the AWS Data Software Competency and the AWS Financial Services Technology Competency, reflecting deep technical expertise and proven customer outcomes. Denodo is available as a fully managed cloud service (Agora) or for deployment in the customer's own AWS account. With Denodo in AWS Marketplace, customers can streamline procurement and consolidate billing.

This strategic collaboration agreement underscores the value Denodo, an AWS Partner, brings to organizations seeking flexibility and greater business value from their data across industries. For more information, please visit: denodo.com/aws

About Denodo

Denodo is the AI data layer company. The award-winning Denodo Platform powers trustworthy agents and applications, transforming enterprise data into reliable insights for analytics and self-service. Organizations worldwide deploy Denodo alongside their data lakehouses to deliver AI-ready, business-ready data in a fraction of the time - achieving up to 4x faster time to insight, 345% ROI, and 10x better performance.

Copyright 2026 GlobeNewswire, Inc.

New Energy Transition Outlook frames five divergent scenarios as geopolitical shock and energy independence reshape the global energy system

LONDON/HOUSTON/SINGAPORE, Nov. 10, 2026 (GLOBE NEWSWIRE) --                                           PRESS RELEASE

As the World Reaches a Fork in the Transition Road, Pursuing Energy Security Could Unexpectedly Lower Emissions, Says Wood Mackenzie

New Energy Transition Outlook frames five divergent scenarios as geopolitical shock and energy independence reshape the global energy system

Key findings include:

Energy security scenario (2.5Celsius) produces lower warming than both Growth First (3Celsius) and the Base Case (2.6Celsius), not through climate policy, but as a by-product of electrification driven by import reduction

The scenarios present a cumulative investment opportunity of US$147 to US$189 trillion through to 2060 for energy and resources companies.

Global liquids demand rises to a peak of approximately 109 mb/d in 2031 in the Base Case

Solar, wind and battery capacity are set to surge 60% by 2030 and six times by 2060 in the Base Case

Nuclear is experiencing a global revival, with the United States holding 53% of the unrisked advanced nuclear pipeline

Global power demand is on track to double by 2060 in the Base Case

FOR IMMEDIATE RELEASE

Wood Mackenzie | www.woodmac.com

The global energy transition has reached a fork in the road, with nations increasingly choosing energy security and economic growth over climate goals. In a finding that challenges conventional assumptions about energy independence, Wood Mackenzie's Energy Transition Outlook 2026-27 reveals that countries pursuing energy security above all else could produce lower warming outcomes than the central base case, not through climate policy, but as an inadvertent by-product of faster electrification driven by import reduction. Electricity is the most efficient way of meeting energy needs as it reduces conversion losses from fossil fuel combustion.

The report for the first time analyses five divergent pathways, introducing two new scenarios, Energy Security (2.5C. C: Celsius) and Growth First (3C), as well as Country Pledges (2C) and Net Zero 2050 (1.5C), all modelled around the Base Case (2.6C), Wood Mackenzie's assessment of the most likely outcome for the energy world.

As geopolitical risk and economic self-interest have moved to the centre of energy decision-making, the inclusion of the two new scenarios better reflects the state of the market and the shift in the energy transition narrative, said Prakash Sharma, Vice President, Head of Scenarios and Technologies at Wood Mackenzie.

"The energy transition has arrived at a genuine crossroads," said Sharma. "The world is no longer moving in one direction. Nations are making fundamentally different choices about how to power their economies, and those choices are producing outcomes that confound conventional wisdom."

Sharma noted that countries cannot simultaneously minimise costs, maximise domestic manufacturing, eliminate supply-chain dependencies, accelerate decarbonisation and limit public spending, adding that this is a time for courage, and countries must accept trade-offs between competing objectives.

"One of our most striking findings this year is that a security-first energy strategy, pursued not out of climate intent but out of necessity, can deliver lower emissions than our central base case. The mechanism is electrification: countries reducing import dependence are building domestic nuclear, geothermal and renewables, and lower emissions would follow longer term.''

Energy Security Scenario: The Electrification Dividend

The report's Energy Security scenario models a world in which the 2026 Strait of Hormuz crisis, which halted 15% to 20% of global oil and LNG flows and pushed Brent crude above US$100 per barrel, becomes a structural turning point. Major economies accelerate their shift away from fossil fuel imports, deploying electrification, renewables and nuclear to reduce exposure to supply chain disruption and chokepoint risk. The result is a warming trajectory of 2.5C by 2100, slightly under the 2.6C Base Case.

Critically, this improvement does not come from heavy deployment of climate-labelled technologies. Hydrogen and carbon capture both remain lower than the base case in the Energy Security scenario as they are trade-exposed, capital-intensive, and difficult to scale without steady policy support.

"The lower emissions are a structural consequence of which technologies a security-first strategy rewards, not which ones it intends to deploy," said Sharma. "Countries would be mindful though that energy security comes at a cost because the race for resilience replaces efficiency and globally optimised supply chains."

By contrast, the Growth First scenario, in which countries prioritise economic expansion above all else to meet growing demand for electricity and artificial intelligence, produces warming above 3C, as existing fossil fuel assets are extended, thermal plant retirements are delayed, and renewables fail to displace fossil fuels at scale.

Fossil Fuels: Shocked, Not Shaken

Despite the geopolitical shock of the Hormuz crisis, fossil fuel demand has proved resilient. Global liquids demand rises to a peak of approximately 109 mb/d in 2031 in Wood Mackenzie's Base Case, staying within 5% of that peak until 2041. In the near term there is no substitute at scale, and price volatility is changing energy policies and investment decisions. Gas outlasts liquids in the Base Case, peaking in 2042, while coal, having peaked in 2024, slides gradually.

Where governments respond to the shock by cutting import dependence, as in the Energy Security scenario, demand diverges more sharply after 2030, falling 8 mb/d below the Base Case by 2040.

The Investment Opportunity

The transition presents a cumulative investment opportunity of US$147 to US$189 trillion to 2060, ranging from the Base Case to Net Zero, with electrification and grid infrastructure requiring roughly half of total capital deployed. Solar, wind and battery capacity are set to surge 60% by 2030 and six times by 2060 in the Base Case. Nuclear is experiencing a global revival, with the United States holding 53% of the unrisked advanced nuclear pipeline, which reached 85 GW in Q3 2026.

Global power demand is on track to double by 2060, driven by electrification, industrial growth, and rapidly expanding data centre capacity, which alone is set to double between 2026 and 2030.

The Climate Scenarios: A Receding Horizon

"The more climate-ambitious pathways, Country Pledges and Net Zero, remain analytically essential as benchmarks," said Sharma. "But the gap between where the world is heading and where these scenarios require it to go has widened again this year. The policy ambition, capital mobilisation and international cooperation they demand are more difficult to achieve today than at any point in the last decade. The fork in the road is real, and right now, most nations are not intentionally taking the faster transition path, resetting priorities towards economic resilience and security. Yet some of these decisions may in fact play a beneficial role in decarbonisation strategies if policies of self-interest unlock or accelerate new technologies."

About Wood Mackenzie's Energy Transition Outlook Wood Mackenzie's Energy Transition Outlook 2026-27 (part of Lens Energy Transition Scenarios) maps five distinct energy transition pathways across 105 energy markets to 2060, covering demand, supply, investment, emissions and emerging technologies. It is Wood Mackenzie's independent assessment of how the global energy system could evolve under divergent geopolitical, economic and policy conditions.

About Wood Mackenzie Wood Mackenzie is the global leader in analytics, insights and proprietary data across the entire energy and natural resources landscape. For over 50 years our work has guided the decisions of the world's most influential energy producers, utilities companies, financial institutions and governments. Now, with the world's energy system more complex and interconnected than ever before, sector-specific views are no longer enough.

That's why we've redefined what's possible with Intelligence Connected: the fusion of our unparalleled proprietary data with the sharpest analytical minds, all supercharged by Synoptic AI, to deliver a clear, interconnected view of the entire value chain. Our trusted team of 2,700 experts across 30 countries breaks siloes and connects industries, markets and regions across the globe to empower our customers to identify risk sooner, spot opportunity faster and make every decision with complete confidence. For more information, visit www.woodmac.com.

You have received this news release from Wood Mackenzie because of the details we hold about you. If the information we have is incorrect you can either provide your updated preferences by contacting our media relations team. If you do not wish to receive this type of email in the future, please reply with "unsubscribe" in the subject header.

Copyright 2026 GlobeNewswire, Inc.

*SCOVELLA was developed to reduce hyperinsulinaemia in insulin-dysregulated horses, a key underlying driver of laminitis - a common, painful inflammatory condition in horses' hooves and significant unmet need in equine health.  

*Laminitis is one of the most significant causes of pain and disability in horses, with one-third of affected horses euthanized within a year of diagnosis.1 

*Once the European Commission follows the CVMP recommendation and grants a marketing authorization, SCOVELLA would be the first therapy approved in the European Union for the reduction of hyperinsulinaemia and the reduction of associated risk of laminitis in horses with Equine Metabolic Syndrome.2 

Ingelheim, Germany - Boehringer Ingelheim, a global leader in animal health, announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) has adopted a positive opinion for SCOVELLA (velagliflozin oral solution), recommending marketing authorization in the European Union (EU). 

"The CVMP's positive opinion for SCOVELLA recognizes the significant need for new treatments for hyperinsulinaemia, a key underlying driver of laminitis in horses," said Saskia Kley, Global Head of Equine at Boehringer Ingelheim. "With this opinion, owners of horses with Equine Metabolic Syndrome in the EU are one step closer to a breakthrough innovation to reduce hyperinsulinaemia and reduce the associated risk of laminitis, one of the most devastating conditions in equine health."

Equine Metabolic Syndrome is a collection of metabolic and clinical features that include insulin dysregulation (ID) as a core component, resulting in an increased risk of laminitis in horses.3

Laminitis is a common and painful inflammatory condition of horses' hooves and one of the most significant causes of pain and disability in horses, with one-third of affected horses euthanized within a year of diagnosis.1 Affecting an estimated one in five horses, insulin dysregulation is estimated to be associated with more than 90% of laminitis cases.4

Once SCOVELLA is approved by the European Commission, it would be the first SGLT-2 inhibitor authorized for horses in the European Union. SCOVELLA was approved and introduced in Great Britain earlier this year.  

With 15 years of research behind SCOVELLA, the SGLT-2 inhibitor is an example of Boehringer Ingelheim's commitment to advance equine health innovations in areas of high unmet need. The oral liquid medication is designed to inhibit glucose reabsorption in the kidneys, leading to a rapid and sustained reduction of insulin to address the main cause of laminitis. 

About Boehringer Ingelheim - Animal Health business  

Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health.   

About Boehringer Ingelheim  

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective. Our approximately 54,300 employees serve over 130 markets to build a healthier tomorrow. Learn more at www.boehringer-ingelheim.com.  

 References:  

1 Luthersson, N., Mannfalk, M., Parkin, T. D., & Harris, P. (2017). Laminitis: risk factors and outcome in a group of Danish horses. Journal of Equine Veterinary Science, 53, 68-73. 

2 Proposed indication: For the reduction of hyperinsulinaemia and reduction of associated risk of laminitis in horses with Equine Metabolic Syndrome not responsive to changes in husbandry and exercise regimen. See the CVMP summary of positive opinion.

3 Bertin, F. R., Bailey, S., Burns, T., De Laat, M., Durham, A. E., Frank, N., ... & Menzies-Gow, N. J. (2024). Recommendations for the diagnosis and management of equine metabolic syndrome (EMS) and insulin dysregulation. Equine Endocrinology Group. 

4 Karikoski, N. P., Horn, I., McGowan, T. W., & McGowan, C. M. (2011). The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital. Domestic animal endocrinology, 41(3), 111-117. 

Copyright 2026 GlobeNewswire, Inc.

Partnership expands onboard 4G/LTE communications and enables crews to identify container issues earlier and respond faster

STERLING, Va., Nov. 10, 2026 (GLOBE NEWSWIRE) -- VIACHAIN, an ORBCOMM company, and Star Solutions today announced a strategic alliance to expand at-sea communications for VIACHAIN-enabled containers, helping vessel crews identify issues and prioritize containers requiring attention.

The companies already work together across hundreds of ships operated by leading shipping lines, supporting hundreds of thousands of smart containers. The alliance builds on that cooperation by bringing Star Solutions' private 4G/LTE networks together with VIACHAIN's connected container technology and CrewView application.

The alliance gives shipping lines an additional way for compatible VIACHAIN-enabled containers to communicate through onboard vessel networks as they adopt 4G/LTE. VIACHAIN technology supports approximately 4 million TEU worldwide.

CrewView helps vessel crews monitor supported refrigerated and dry containers, flagging temperature deviations, power interruptions and other exceptions. Crews can focus checks on containers that need attention rather than relying on routine rounds alone, helping protect cargo, use their time more effectively and reduce unnecessary exposure to onboard hazards.

"Our goal is straightforward: keep container information available at sea and make it useful to crews," said Chip Lebovitz, SVP and GM of VIACHAIN. "When crew members can quickly see what needs attention, they can spend less time looking for problems and more time addressing them. This alliance advances VIACHAIN's broader mission to bring greater accountability and operational intelligence for all stakeholders in the supply chain."

"Private cellular networks help shipping lines put their connected-container investments to work onboard," said Jack Mar, CEO of Star Solutions. "This alliance brings our 4G/LTE expertise together with VIACHAIN's applications to make that easier for operators."

About VIACHAIN, an ORBCOMM company

VIACHAIN is the accountability platform for cargo-carrying assets. It provides a trusted record of each asset's location, condition, movement and use, and transforms that data into operational intelligence that helps customers protect cargo, improve asset utilization and reduce avoidable costs. With more than 2 million connected assets across some of the world's largest shipping lines, trucking fleets, logistics providers and railroads, VIACHAIN is where IoT powers smart supply chains.

About Star Solutions

Star Solutions is a leading provider of end-to-end 2G to 5G mobile wireless network infrastructure, specializing in Core Network and RAN solutions. Trusted by operators in over 30 countries, the company delivers scalable, easy-to-deploy mobile networks for rural and remote network operators, emergency organizations, and over 800 private industrial networks using Industry 4.0 applications including mining, agriculture, airports, transportation, maritime and ports. From design to deployment and support, Star Solutions offers full-lifecycle mobile network expertise.

Copyright 2026 GlobeNewswire, Inc.

Fourth-generation silicon carbide platform based on a trench architecture reduces losses while enabling more compact power systems across AI, EV and energy applications.

Summary

onsemi introduced EliteSiC M4, its fourth-generation silicon carbide platform built on a trench architecture, delivering up to 30% higher power density and 35% lower losses compared with the previous generation. By advancing conduction and switching performance, EliteSiC M4 enables more efficient, power-dense systems for AI data centers, electric vehicles and energy infrastructure.

News Highlights:

EliteSiC M4 delivers higher power density and lower losses enabling customers to increase performance and efficiency while optimizing system size and managing cooling requirements

Extends onsemi's proven SiC leadership, building on more than 16 billion miles of real-world operation

EliteSiC M4 750 V automotive traction bare die available now, with additional voltage options up to 1200 V expected in 2027

SCOTTSDALE, Ariz., Nov. 10, 2026 (GLOBE NEWSWIRE) -- onsemi (Nasdaq: ON) today introduced EliteSiC M4, its fourth-generation silicon carbide (SiC) platform built on a trench architecture and designed to set a new performance benchmark for next-generation power systems.

With industry-leading conduction and switching performance, EliteSiC M4 gives customers greater design freedom to increase power density and efficiency up to 30% and lower losses by 35%, enabling more efficient, power-dense systems across EVs, AI data center and industrial applications.

"Power requirements are rising faster than the physical infrastructure around them. The next generation of power systems will require the ability to deliver more power, more efficiently and in less space," said Achyut Shah, Group President of the Power Solutions Group at onsemi. "With more than 16 billion miles of proven silicon carbide operation in vehicles around the world, EliteSiC M4 is combining that foundation of reliability with the performance customers need to rethink the balance among power, efficiency, size and cost."

Delivering More Power Within Real-World Constraints

The growth of AI, electrification and energy infrastructure is creating a common challenge for power-system designers - delivering significantly more power without proportional increases in size, energy losses, and cooling requirements. EliteSiC M4 addresses that challenge by expanding the power and efficiency available within existing system constraints, giving customers greater flexibility to scale AI infrastructure, electric vehicles and industrial systems.

Across its key markets, EliteSiC M4 translates these technology advances into distinct system-level benefits:

AI Data Centers: Scaling compute without scaling power infrastructure at the same rate. Higher-density power conversion helps data centers get more compute from every megawatt, maximizing capacity while reducing the supporting infrastructure required per unit of compute

Electric Vehicles: Getting more performance from the electric drivetrain. More compact, efficient traction inverters can help automakers improve vehicle range

Energy Infrastructure: Making more of every unit of energy. More efficient, higher-density power conversion helps solar, energy storage and other high-voltage systems reduce conversion losses

"As vehicle power levels increase, traction-inverter design becomes a tighter balancing act between efficiency, thermal performance, power density and reliability," said Harald Hartel, Vice President, BU eMotor Controls at Schaeffler AG. "Higher efficiency and power density can give us greater flexibility to optimize the traction inverter for range, thermal performance and packaging, which are increasingly important as electrified powertrains become more demanding."

A New Architecture for Higher Power Density and Efficiency

EliteSiC M4 improves conduction and switching performance without compromising reliability. Key improvements over the previous generation include:

Improvement in specific on-resistance (RSP): Reduces specific RSP between 20% - 50%, while enabling faster switching

Lower switching losses: Improves switching figures of merit by 67% in hard-switching and 50% in soft-switching, supporting compact power-supply designs

Broad packaging flexibility: Designed to support existing packages, including top-side-cooled surface-mount packages and high-power modules

Ruggedness for demanding applications: The platform is also designed for demanding operating environments, with qualification supporting temperatures of 185?C and above, enabling use in high-voltage automotive and space applications

Availability

The EliteSiC M4 750 V bare die for automotive traction inverters is available now. Additional product offerings for a range of voltages up to 1200 V are expected to be available beginning in 2027.

More Information:

Learn More about EliteSiC Solutions

Media Assets: onsemi M4 Platform

White Paper: Advancing Power Density with EliteSiC M4

About onsemi

onsemi (Nasdaq: ON) delivers intelligent power and sensing technologies that enable electrification, energy efficiency, safety, and automation across automotive, industrial, and AI data center end-markets. With a highly differentiated and innovative product portfolio, onsemi helps customers solve complex challenges to achieve higher efficiency, improved performance, and lower system cost, while supporting a safer, cleaner, and more energy-efficient world. The company is part of the S&P 500? index. Learn more at www.onsemi.com.

onsemi and the onsemi logo are trademarks of Semiconductor Components Industries, LLC. All other brand and product names appearing in this document are registered trademarks or trademarks of their respective holders. Although the Company references its website in this news release, information on the website is not to be incorporated herein.

Copyright 2026 GlobeNewswire, Inc.

MILAN, Nov. 10, 2026 (GLOBE NEWSWIRE) -- LYVA, LUYUAN Group's global premium smart-mobility brand, has concluded its European debut at EICMA 2026 with five concept models, industry media visits and the launch of its Global Co-Creation programme.

Cargo R07 and the Z05 multi-folding electric kickscooter attracted strong interest from visitors. European users were particularly drawn to their distinctive mechanical structures, practical functions and design aesthetics. Cargo R07 received especially positive feedback from families, with many visitors taking an interest in its potential for carrying children and everyday goods.

Unlike conventional front-loading cargo designs, Cargo R07 is an electric-assist tricycle with a rear cargo platform. Its tilting architecture allows the vehicle to lean through corners while keeping the cargo platform stable, supporting a more comfortable and reassuring ride for both passengers and goods. The design resonated with families seeking a practical mobility solution for daily travel, school runs and short-distance transportation.

Z05 features a multi-folding structure that creates an ultra-compact package for storage in car boots and carrying on public transport. Visitors responded positively to its convenience and portability, particularly for multimodal travel and last-mile commuting.

The wider portfolio included T05, an e-trekking bike concept with a one-piece die-cast magnesium-alloy frame, and the GX03 and GX05 E-dirtbike concepts. GX05 demonstrated approximately five-minute disassembly, showing how its modular structure can simplify storage for users without garages and make it easier to transport the vehicle in an SUV for outdoor riding.

Alongside the vehicles, LYVA presented an integrated technology platform covering power, energy and AI-assisted riding systems. Liquid-cooled motors, electronic shifting and adaptive torque control deliver smoother and more responsive riding.

Journalists from Moto.it,1000PS and vaielettrico.it visited the booth for product presentations and interviews. The LYVA Global Co-Creation programme welcomed its first three Co-Creators. With100 spots available, riders can join via LYVA's website and social media to contribute through test rides, reviews and feedback.

Following EICMA, LYVA will continue to prioritise European engineering and market development. EPP Engineering supports local engineering development and validation, while LYVA plans to combine online channels with specialist European dealers.

About LYVA

LYVA is a premium brand established by LUYUAN Group (HK.02451), focused on smart mobility and intelligent light-mobility solutions. LYVA brings together technology and design to address diverse commuting, recreational and everyday mobility needs.

Copyright 2026 GlobeNewswire, Inc.

New oscilloscope brings advanced capabilities, an intuitive experience and a compact design at an accessible price to university students, educators and engineers

BEAVERTON, Ore., Nov. 10, 2026 (GLOBE NEWSWIRE) --

Engineering starts with a question. Today, Tektronix introduces the 1 Series, a compact digital phosphor oscilloscope (DPO) designed to give more people the tools to pursue the answer, from university students making their first measurements to experienced engineers who need a versatile instrument across a range of engineering environments.  

Starting at under $500, the 1 Series combines advanced acquisition and analysis capabilities with an intuitive user interface. With up to four analog channels, 12-bit vertical resolution, serial protocol analysis and integrated signal generation on select models, the 1 Series gives students room to move beyond basic measurements while giving experienced engineers the performance and tools for everyday design, debug and test. 

Designed with a compact footprint, the 1 Series brings capable measurement to more places, whether on the bench, across the lab, or in a remote work setup. That combination of capability, compact design and accessible price gives the instrument a role across education, embedded design and debug, electronics test and repair, automated test and general-purpose engineering. 

"Engineering is a constant learning curve. The earlier the right tools get into an engineer's hands, the sooner they can connect theory with what they actually see and measure, and the better prepared they are to solve real problems," said Daryl Ellis, Vice President and General Manager of Signal Acquisition and Analysis Portfolio at Tektronix. "We designed the 1 Series to give students and educators access to serious measurement capability early, while giving engineers at every level an instrument that's capable, approachable and flexible enough to keep close at hand." 

Built for the next question 

An oscilloscope makes the invisible visible. For a university student, seeing an electrical signal and measuring how it responds can connect a concept learned in a textbook or simulation with the behavior of real-world signals. For an experienced engineer, the same capabilities can help reveal why a design isn't behaving as expected and where to look next. The 1 Series brings those experiences together in an approachable instrument with capabilities that extend well beyond basic waveform viewing.  

Key capabilities include: 

More signals, more detail: Up to four analog channels, 12-bit vertical resolution, up to 200 MHz bandwidth, 1.25 GS/s sample rate and 10 Mpoints of record length per channel provide the acquisition performance to investigate more complex designs.  

Deeper insight into embedded systems: Serial protocol decode for I2C, SPI and UART, along with FFT, limit testing and automated measurements, helps engineers move from seeing a signal to understanding its behavior. 

More capability in one instrument: Select models add an integrated 25 MHz arbitrary function generator (AFG) and Bode plot analysis, allowing engineers to generate signals, measure circuit response and analyze behavior without adding another instrument to the bench. 

An intuitive experience: A 7-inch multi-touchscreen brings the TekScope user interface found across the Tektronix oscilloscope portfolio to the 1 Series. The common UI shortens the ramp from first use to useful measurement for engineers learning the instrument, while giving experienced engineers a familiar way to work. 

For educators, the 1 Series brings hands-on learning into the instrument itself. Instructors can disable automated settings and measurements to keep students focused on fundamental signal concepts, while e*Scope extends access beyond the lab and lets instructors view student work remotely. An extensive help system, with direct access to video demonstrations and measurement how-tos, provides support as students learn to make and interpret measurements, then apply those skills to more sophisticated project work. 

The familiar TekScope interface also creates continuity across the Tektronix oscilloscope portfolio. Skills and workflows learned on the 1 Series transfer to higher-performance Tektronix oscilloscopes, reducing the need to relearn how to interact with the instrument as measurement requirements advance. For experienced engineers, that continuity works in the other direction as well, bringing familiar workflows to a smaller, more accessible instrument. 

Designed for wherever engineering happens 

At just 4.8 pounds, the 1 Series is easy to move between work locations, while its 4-inch depth helps it fit where space is limited. VESA mounting and an optional rackmount kit provide additional flexibility in how and where the instrument is deployed. Combined with its measurement capacity and accessible price, that compact design also makes the 1 Series a practical additional scope for everyday work or added measurement capacity without tying up a higher-performance instrument.  

The 1 Series also fits into remote and automated workflows. Ethernet and USB connectivity support remote and programmatic control, while Python-based automation allows engineers to integrate the scope into larger test systems and software workflows.  

As Tektronix works to put powerful measurement tools in the hands of more engineers, the company is also exploring how AI can make the expertise behind those tools easier to access and apply. 

Extending discovery with AI  

Beginning today, customers can be among the first to access the Tek Intelligence? connector, a new way to connect their AI agent of choice with trusted Tektronix measurement knowledge, tools and supported instruments across the portfolio.  

With the 1 Series, engineers can tell their AI agent what they are trying to accomplish in plain language, then the agent can use the connector to translate that intent into validated instrument commands to directly control the instrument or build working automation. For students and educators, this creates a more intuitive way to configure and control the instrument. For experienced engineers, it can reduce the steps between identifying a problem and getting to the measurements needed to understand it.  

The connector offers a first look at how Tektronix is enabling a new interaction between engineers, AI, and their instruments, informed by 80 years of measurement expertise. Request early access at dev.tek.com/en/tek-intelligence. 

Availability 

The 1 Series DPO is available today. See where measurement can go next at tek.com/1seriesdpo. 

About Tektronix 

Tektronix is the partner engineers have trusted to measure, discover and innovate for 80 years. Today we deliver test and measurement solutions that unite precision with simplicity, helping engineers accelerate breakthroughs that shape a better tomorrow. Learn more at tek.com/newsroom. 

Tektronix is a registered trademark of Tektronix, Inc. All other trade names referenced are the service marks, trademarks or registered trademarks of their respective companies. Use of Tek Intelligence is subject to the end user license agreement available at https://www.tek.com/en/terms_and_conditions. 

SOURCE: Tektronix, Inc. 

Copyright 2026 GlobeNewswire, Inc.